Global Biological Drugs Market
Global Market Study Biological Drugs: North America to Remain as the Largest Biological Drug Market during the Forecast Period (2014-2020)
Biological Drugs Market Segmented By Biologic Therapeutic Drugs, Biologic Medicines with Enbrel, Lantus, Neulasta, Avonex, NovoLog Therapeutic Protein
Primary source of biological drugs are living cells. These drugs are used in treatment and prevention of chronic diseases such as cancer, severe blood disorders and few other auto-immune diseases. The complex structure of biological drugs separates them from other conventional drug types. Demand for biological drugs has grown in recent past, which is attributed to the increasing prevalence of chronic diseases across the globe. In addition, government organization are endorsing the usage of biological drugs, which in turn is translating into growth of global biological drugs market. PMR indicates that the global biological drugs market will witness a healthy CAGR of over 10% during the forecast period to reach US$ 287,139.7 by 2020,
Find Out More about the Report Coverage
Some of the major players in the biological drugs market:
- Pfizer Inc.
- Abbott Laboratories.
- Novartis AG.
- Eli Lilly and Company.
- GlaxoSmithKline plc.
- Bristol-Myers Squibb Company.
- Merck & Co., Inc.
- Amgen Inc.
- Baxter International Inc.
- Biogen Idec.
These key market players have been profiled on the basis of attributes such as company overview, recent developments, growth strategies, sustainability, and financial overview.
Key Market Dynamics
Demand for biological drugs is expected to gain traction in the near future owing to the worldwide increase in geriatric population and higher prevalence of chronic diseases. Moreover, the global biological market is benefiting from various healthcare awareness initiatives taken by both public and private organizations. Likewise, innovation in biomedical technology and ongoing R&D programs are anticipated to highlight further scope for market expansion. On the other hand, issues related to patent expiry of bestselling drugs and pricey nature of such drugs are expected to inhibit the overall market growth. Similarly, additional threats of severe side effects and associated risks from injectable biological drugs may also negatively influence the growth of the market.
Customize this Report
Explore Intelligence Tailored to Your Business Goals.
The global biological drugs market has been classified into therapeutic protein, monoclonal antibody, vaccine and region.
On the basis of therapeutic protein, the market is segmented into enbrel, neulasta, novoLog, humalog, rebif, epogen, levemir, betaseron, eylea, lantus, avonex, aranesp, victoza and neupogen. Enbrel is the most dominating segment and is expected to grow at the fastest rate during the forecast period. By monoclonal antibody (mAb), the market is segmented into, remicade, avastin, lucentis, humira, rituxan and herceptin. In addition, the humira segment will continue to dominate the market over the forecast period. Based on vaccine, the market is segmented into prenvar 13, fluzone, cervarix, gardasil and varivax. Demand for prevnar 13 is expected to be higher compared to other vaccines through 2020.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
On the basis of region, the global biological drugs market is segmented into North America, Asia Pacific, Europe and rest of the world (RoW). North America will continue to be the most lucrative market for biological drugs during the forecast period. In addition, the market in North America is expected to be worth 147,783.8 Million by 2020, expanding at 10.9% CAGR over the forecast period. Increasing demand for biological drugs to treat diseases such as diabetes and cancer is expected to support growth of the market in the region.
Moreover, frequent healthcare awareness programs conducted by various public organizations is further influencing the market growth in North America. The market in Europe, is primarily driven by demand for biological drugs from the geriatric population of the region. According to a UN report, by 2025 elderly population in Germany is expected to cover 33.2% of the total population in the country. In Asia, factors such as encouraging government initiatives and higher funding for establishing new biotech companies, drug manufacturing facilities and life science institutions are expected to stimulate the biological drugs market in the region. Moreover, the cost of drug manufacturing in Asia is lower compared to other regions, which in turn is alluring the overseas companies to setup manufacturing plants in the region.
Explore Persistence Market Research’s expertise in promulgation of the business !
Key Market Participants
Key market players operating in the global biological drugs market include Merck & Co., Inc., Abbott Laboratories, Eli Lilly and Company, Baxter International Inc., Novartis AG, Pfizer Inc., Biogen Idec, Bristol-Myers Squibb Company, Amgen Inc., and GlaxoSmithKline plc.